Summary of product characteristics (SmPC)
The target audience for the SmPC are healthcare professionals with medical professional background. The applicant must ensure that the SmPC is of high quality. The concept of plain language should be used.
How to write a good text:
- Write in Norwegian
- Write clearly
- Write to healthcare professionals
- Use standardised translations and abbreviations
1. Write in Norwegian
It is important that the translated Norwegian text has the same meaning as the English text (faithful translation). There are differences between English and Norwegian grammar. Sentence structure and word order are often different. Direct translation from English to Norwegian can lead to complicated wording and incorrect translation. Split long sentences if possible.
2. Write clearly
Use short sentences and write in an active voice. Avoid using extra nouns. Use verbs instead of nouns where possible. The message should not be disturbed by ambiguous and unclear language.
3. Write to healthcare professionals
Use well-established Norwegian medical terms as much as possible. Some medical terms are identical in English and Norwegian.
4. Standardised translations and abbreviations
The following translations should always be used in the SmPC.
- active substance – virkestoff
- adverse effects/adverse drug reactions – bivirkninger
- adverse events – uheldige hendelser
- drug/substance – legemiddel
- efficacy/effectivity – effekt
- herbal medicinal product – plantebasert legemiddel
- medicinal product – legemiddel
- patient alert card /patient reminder card – pasientkort
- QD – én gang daglig
- BID – to ganger daglig
- TID – tre ganger daglig
- QID – fire ganger daglig
Package leaflet (PIL)
Applicants must ensure that the package leaflet (PIL) always is of high quality. The target audience for the PIL is the patient, therefore the PIL should be easy to read and understand (written in plain language).
How to write a good text:
- Write in Norwegian
- Write clearly
- Write to the patient
1. Write in Norwegian
It is important that the translated Norwegian text has the same meaning as the English text (faithful translation). There are differences between Norwegian and English grammar. Sentence structure and word order are often different. Direct translation from English to Norwegian can lead to complicated wording and incorrect translation. Split long sentences if possible.
2. Write clearly
Use short sentences and write in an active voice. Use verbs instead of nouns where possible. The message should not be disturbed by ambiguous and unclear language.
3. Write to the patient
Foreign words are used to a greater extent in the English language, than in Norwegian. Medical terms should always be translated into patient friendly terms and language. The medical term may in some cases be kept in brackets.
Excipients guideline with Norwegian translations
Excipients in medicinal products should be listed qualitatively in the package leaflet. Several of these should be accompanied by information that is of importance to the patient. Such excipients are listed in the
New MAs shall comply with this guideline. Existing MAs must update the package leaflet in the next variation concerning the product information or renewal procedure.
Starting February 12, 2020, the Blue box sentences are no longer required in the package leaflets. These sentences must be removed with the next variation affecting the product information and cannot be sent as a separate 61(3) notification. If no variations to the product information are planned, the Blue box sentences may be removed with the update of the new QRD template (version 4.1, 02/2020). The Norwegian Medicines Agency encourages applicants to replace the statements on driving and overdose with information specific to the drug, if applicable.
The following sentences must be removed from the package leaflet
- Legal status Under punkt 1: Hvis preparatet er unntatt fra reseptplikt må det fremgå av pakningsvedlegget. Tilhørende indikasjonsområde og dosering inkluderes.
- Under punkt 1: "Vær oppmerksom på at legen kan ha foreskrevet legemidlet til en annen bruk og/eller med en annen dosering enn angitt i pakningsvedlegget. Følg alltid legens forskrivning som er angitt på apoteketiketten."
- Under overskriften: Kjøring og bruk av maskiner: "Du må bare kjøre bil eller utføre risikofylt arbeid når det er trygt for deg. Legemidler kan påvirke din evne til å kjøre bil eller utføre risikofylt arbeid. Les informasjonen i pakningsvedlegget nøye. Er du i tvil må du snakke med lege eller apotek. "
- Under overskriften: Dersom du tar for mye av X: "Kontakt lege, sykehus eller Giftinformasjonen (tlf. 22 59 13 00) hvis du har fått i deg for mye legemiddel eller hvis barn har fått i seg legemiddel ved et uhell. For andre spørsmål om legemidlet, kontakt lege eller apotek."
The national guideline on packaging is based on the Norwegian regulation (Forskrift om legemidler) § 3-29-§ 3-41 and applies to human and veterinary medicinal products.
Packaging - Management and guideline
Guideline and Q&A on Nordic packages
The Guideline on Nordic Packages document contains general information on Nordic packages, whereas the Frequently Asked Questions document gives detailed advice on different package issues. These documents apply to medicinal products for both human and veterinary use. Marketing authorisation holders may submit questions regarding issues relating to Nordic packages. For this purpose a specific form, Question to the Nordic package group should be used. All documents are published on the MPA website.
Regarding requests for common Nordic assessment for mock-ups, please use the form ”Request for a Nordic mock- up cooperation for a marketing authorisation procedure/61(3) notification (hum)/C.II.6 variation (vet)”. The request form and further information about this procedure is found on the MPA website.
61(3) notifications for information only
Some changes concerning the labelling can be submitted as a 61(3) notification for information only. The notification will be noted and no approval will be issued. See the following link for requirements: 61(3) notification for information only (in Norwegian).
Blue box requirements
Blue box is additional information on labelling that may be required or permitted nationally in accordance with Articles 58 and 64 of Directive 2001/82/EC
There are no requirement for the legal status to appear on the label, except for packages intended for dose dispensing. Norwegian text required on the labelling: «Kun til dosedispensering»
Identification and Authenticity
The Nordic number is required on the outer labelling of all medicinal products. It is written as "Vnr XX XX XX". The EAN code (bar code) is accepted but not required on the labelling. For further information and application for Nordic article Numbers, please refer to http://wiki.vnr.fi/.
The EAN code (bar code) is accepted but not required on the labelling.
Symbols and Pictograms
Medicinal products containing inflammable material must bear the international warning symbol.
Medicinal products which reduce the ability to drive or operate machines must have a warning triangle on the outer and inner packaging.
The warning triangle - list and Q&A
All medicinal products for human use containing an active substance stated in the warning triangle list from the NoMA, shall bear the warning triangle. The requirement applies regardless of procedure. The warning triangle is a national blue box element.
The tip of the triangle points upwards. It is a red triangle on a white background. Its size is adapted to fit the labelling; its sides are usually 10 mm long and the width of the frame is usually 2 mm.
Nordic article number (Varenummer (Vnr)) - general information
According to the national regulations, the outer packaging must contain a Nordic article number. Nordic Number Center in Finland is responsible for the allocation of numbers . For further information and details on how to apply for a Nordic article number, see http://wiki.vnr.fi/.
Change in trade name requires a change of Nordic article number (Vnr)
To change the Nordic article number:
- Submit an application for a new Nordic article number to PIC in Finland.
- Inform Farmalogg about the new article number. It must be registered and processed as a new product in Farmalogg.
Only two article numbers can be in sale at the same time, due to the functionality of the FEST register. If a third article number is registered for sale, the oldest article number will lose reimbursement.
The article number provides a unique identity for a specific package, which is essential when buying and selling medicinal products. Each article number carries information necessary for the proper logistics and handling of the medicinal product at pharmacies, wholesalers, suppliers and prescribers. The article number is also a prerequisite for all public statistics. All medicinal products in Farmalogg's national article register (Vareregisteret) must have an article number, and all the electronic information about a medicinal product is linked to the article number.
For information regarding Farmaloggs national article register (Vareregisteret), contact email@example.com
Unique identifier/FMD Q&A
For information about the unique identifier on labelling/mock-ups (human) in connection with the Falsified Medicines Directive.
2D barcode on immediate packaging
For some medicinal products, LIS (Sykehusinnkjøp HF, divisjon legemidler) requires the inclusion of a 2D barcode on the immediate packaging. The Norwegian Medicines Agency is often asked if LIS can make such a demand:
- Yes, LIS can require a 2D barcode on the immediate packaging. The legislation does not prohibit the use of a 2D barcode on the immediate packaging. However, the inclusion of a 2D barcode is not a requirement in the legislation.
- The 2D barcode can be placed on the immediate packaging, as long as the statutory information is included and the readability requirement of the statutory information is fulfilled.
- The 2D barcode can include information already included on the labelling, e.g. PC (product code) (name, strength and pharmaceutical form), shelf life and batch number.
A mock-up of the immediate packaging must be approved with the 2D barcode in all procedures. For medicinal products approved through the purely national procedure and the MRP/DCP a 61(3) Notification can be submitted to firstname.lastname@example.org. The changes can also be included in an ongoing variation including update of the mock-ups.
For centrally authorised medicinal products, the mock-ups are approved by the EMA.
Norwegian QRD product information templates
The Best Practice Guide on the submission of high quality national translations (published by CMDh) aims to improve the quality of translations of the agreed product information submitted during the national implementation phase of the procedures.
Updating Norwegian product information by new
Common practice for updating the product information of nationally authorised medicinal products (MRP/DCP and purely national procedure):
- The product information should be updated according to the current template at the time of submission, i.e. applications submitted before the new template was published are processed according to the old template. If not other is advised by Reference member state (RMS) or national authority.
- The product information should be updated with the next variation that affect the product information.
- If no variation concerning the product information is planned, the MA-holder may submit a notification to email@example.com within 2-3 years.
For medicinal products authorised through centralized procedures, please see EMA's website.
Revision of Human QRD template – Version 10.1, 06/2019
Version 10.1, 06/2019 of the human QRD template was published on the EMA's website on 28 June, 2019.
Among the changes, new requirements for the traceability of biological medicinal products has been introduced under section 4.4 Warnings and precautions.
Please note that in addition some linguistics updates have been made in the Norwegian translation.
For detailed information on the implementation of the new version, see EMA's website.
Reporting of adverse reactions in SmPC and PIL
For medicinal products authorised through MRP/DCP and national procedure the texts below shall be included in both printed and electronic version of the product information.
For medicinal products authorised through CP the texts below shall be included in the printed version of the product information only.
SmPC Reporting of suspected adverse reactions (section 4.8):
Melding av mistenkte bivirkninger
Melding av mistenkte bivirkninger etter godkjenning av legemidlet er viktig. Det gjør det mulig å overvåke forholdet mellom nytte og risiko for legemidlet kontinuerlig. Helsepersonell oppfordres til å melde enhver mistenkt bivirkning. Dette gjøres via meldeskjema som finnes på nettsiden til Statens legemiddelverk: www.legemiddelverket.no/meldeskjema.
Package leaflet Reporting of side effects (section 4):
Melding av bivirkninger
Kontakt <,> dersom du opplever bivirkninger. Dette gjelder også bivirkninger som ikke er nevnt i pakningsvedlegget. Du kan også melde fra om bivirkninger direkte via meldeskjema som finnes på nettsiden til Statens legemiddelverk: www.legemiddelverket.no/pasientmelding. Ved å melde fra om bivirkninger bidrar du med informasjon om sikkerheten ved bruk av dette legemidlet.
Articles that are QP-released 6 months or more after the approval date must come with packaging material.
Naming of medicinal products
Guideline for the naming of medicinal products
Warning statements for excipients in the labelling and PIL.
Annex to Excipients guideline in English and Norwegian.